Patients in both cohorts must have progressive disease following prior therapy; specifically:\r\n* Cohort 1 (NSCLC): Patients must have evidence of radiologic or clinical disease progression during previous treatment with systemic PD-1 directed therapy and/or have been deemed not to derive clinical benefit from PD-1 directed treatment; this includes patients who demonstrated an initial response and subsequent progression; no prior treatment with chemotherapy or targeted agents are required; intervening therapy is allowed between previous PD-1 directed treatment and there is no required interval from prior PD-1 treatment required; PD-1 directed treatment includes treatment with antibodies targeting the PD-1 receptor such as pembrolizumab or nivolumab, as well as PD-L1 targeted antibodies such as MEDI4736 (durvalumab), atezolizumab and avelumab; these agents may have been administered as part of a clinical trial\r\n* Cohort 2 (colorectal cancer): Patients must have progressed on >= one line chemotherapy
No prior treatment with any therapy on the PD-1/PD-L1 axis
Prior PD-1- or PD-L1-directed therapy.
Prior treatment with an agent that blocks the PD-1/PD-Ligand 1 pathway;
Prior therapy with a PD-1, PD-L1, PD-L2 or CTLA-4 inhibitor or a lung cancer-specific vaccine therapy
Prior therapy with any antibody or drug targeting T-cell coregulatory proteins (immune checkpoints), such as PD-1, PD-L1, or cytotoxic T lymphocyte antigen-4.
Tissue specimen available for retrospective analysis of PD-1, PD-L1, LAG-3, and MHC-II expression
Histologically or cytologically confirmed unresectable or metastatic melanoma that had confirmed progressive disease during treatment with anti-PD-1/PD-L1 therapy. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.
Previous exposure to any immunomodulatory agents (e.g., anti- CD40, CTLA-4, PD-1/PD-L1, IDO inhibitors) or any other immunomodulatory agent (with the following (except PD-1/PD-L1 in subjects with unresectable or metastatic melanoma)
History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma
Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy.
Patient has received prior immunotherapy with inhibitors of PD-1/PD-L1 axis
Prior treatment with combination CTLA-4 and PD-1/PD-L1 blockade.
Prior treatment with a PD-1/PD-L1 inhibitor
For patients with mCRPC, prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1 pathway.
Patient may be second- or later-line NSCLC patient, and must have documented radiological and/or clinical progression on a prior anti-PD-1/PD-L1 containing therapy.
Prior treatment with a platinum-based (cisplatin or carboplatin) regimen and a PD-1 or PD-L1 monoclonal antibody (either in combination or sequentially).
Prior treatment with a PD-1, PD-L1 or PD-L2 inhibitor
Prior PD-1/PD-L1 treatment is permitted in Part B of this study, but only subjects who have progressed on their prior PD-1/PD-L1 treatment without a partial or complete response, and without discontinuing for drug-related toxicity are eligible for Part B.
Patients undergoing a minimally invasive PD, such as laparoscopic or robotic PD
For Phase 1a and 1b, prior PD-1 or PD-L1 therapy or other immunotherapy is allowed, if the following criteria are met:
Prior treatment with PD-1 or PD-L1 inhibitor
Patients must have evidence of radiologic or clinical disease progression during or within 6 months of previous treatment with systemic PD-1 directed therapy, or have stable disease on prior PD-1 therapy (at least 6 doses) and/or have been deemed not to derive clinical benefit from PD-1 directed treatment; PD-1 directed treatment includes treatment with antibodies targeting the PD-1 receptor such as pembrolizumab or nivolumab, as well as PD-L1 targeted antibodies such as durvalumab; these agents may have been administered as part of a clinical trial, and/or in combination with other immunologic agents such as CTLA-4 inhibitors or other investigational agents
Inclusion Criteria (Phase 1 and 2 Melanoma and HNSCC patients)\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.\n\n          -  Life expectancy of at least 6 months.\n\n          -  Have provided tissue biopsy sample enough for PD-L1 expression level testing and RNA\n             expression profiling.\n\n        Inclusion Criteria: Phase 2 Melanoma patients\n\n          -  Histologically or cytologically confirmed unresectable or metastatic (stage IV)\n             melanoma.\n\n          -  Have at least 2 sites that qualify as measurable target lesions per RECIST 1.1 of\n             which 1 must be palpable or visualized by ultrasound and easily accessible to multiple\n             intratumoral injections.\n\n          -  For patients with progressive disease (PD) while receiving anti-PD-1/L1 therapy, must\n             have documented PD per RECIST v1.1 while receiving a prior anti-PD-1/L1 therapy.\n\n        Inclusion Criteria: Phase 2 HNSCC patients\n\n          -  Histologically or cytologically confirmed recurrent or metastatic HNSCC that could not\n             be treated with curative intent.\n\n          -  Have at least 1 measurable target lesion per RECIST 1.1, which must be accessible and\n             amenable to multiple intratumoral injections.\n\n          -  Must have documented PD per RECIST v1.1 while receiving a prior anti-PD-1/L1 therapy.\n\n        Exclusion Criteria: (Phase 1 and 2 Melanoma and HNSCC patients)\n\n          -  Received systemic chemotherapy or biological cancer therapy (except anti-PD-1/L1\n             therapy) within 3 weeks prior to study enrollment.\n\n          -  Received prior radiotherapy within 2 weeks of start of study therapy.\n\n          -  Received small molecule inhibitor targeted therapy, such as tyrosine kinase\n             inhibitors, within 2 weeks prior to study enrollment.\n\n          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other\n             form of immunosuppressive therapy (including immune modulators or systemic\n             corticosteroids) within 7 days prior to study enrollment\n\n          -  Is expected to require any other form of anti-cancer therapy while in the trial.\n\n          -  Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).\n\n          -  History of or current uveal or ocular melanoma.\n\n          -  Active infection including cytomegalovirus.\n\n          -  Active autoimmune disease requiring systemic treatment in the past 2 years or a\n             disease that requires immunosuppressive medication. Replacement therapy is not\n             considered a form of systemic treatment.\n\n          -  Current pneumonitis or history of (non-infectious) pneumonitis that required steroids.\n\n          -  Known active central nervous system metastases or carcinomatous meningitis.\n\n          -  Use of any investigational agent within the last 28 days prior to study enrollment.\n\n          -  Has received a live-virus vaccination within 30 days of planned treatment start.\n             Seasonal flu vaccines that do not contain live virus are permitted.\n\n          -  Any known additional malignancy that is progressing or requires active treatment,\n             except for melanoma and HNSCC.\n\n        Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 1 and 5 only)\n\n          -  Any prior combination therapy targeting immunoregulatory receptors or mechanisms and\n             an anti-PD-1/L1 agent or an investigational agent targeting immunoregulatory receptors\n\n          -  Prior therapy with an anti PD 1/L1 agent\n\n        Exclusion Criteria: (Phase 2, Melanoma Expansion Cohort 2 only)\n\n        • Any prior combination therapy involving agents given by intratumoral injection that\n        target the innate immune pathway or system.\n\n        Exclusion Criteria: (Phase 2, HNSCC Expansion Cohorts 3 and 6 only)\n\n          -  Prior therapy with an anti PD 1/L1 agent\n\n          -  Require treatment on anticoagulation therapy.\n\n        Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 4 and 7 only)\n\n          -  Any prior combination therapy involving agents given by intratumoral injection that\n             target the innate immune pathway or system.\n\n          -  Require treatment on anticoagulation therapy
Prior therapy with specific antibody/drug targeting immune or coregulatory or costimulatory proteins (such as checkpoints e.g., PD-1 or PD L1, 4-1BB, OX40 or CTLA-4 antibodies).
Any prior immunologic cancer therapy with systemic inhibitors of the PD-1 or CTLA-4 pathway
Patients can be treated either in first line or in the refractory setting; PD-L1 positivity is not required for enrollment
Patient has received immunotherapy with inhibitors of PD-1 or PD-L1, or CTLA-4 blocking antibodies within 4 months prior to study day 1
Patient must have previously received one (but no more) line of previous therapy with an anti-PD-1/PD-L1 mAb therapy either alone or in combination and have either progressed or responded and then stopped responding.
Patients must have previously received at least one line (and not more than 2 lines) of previous therapy with an anti-PD-1/PD-L1 mAb therapy, either alone or in combination, and have either progressed or responded and then stopped responding.
Previous treatment with a PD-1 or PD-L1 inhibitor with documented progression of disease on most recent computed tomography (CT) scan; progression of disease is defined as 1) the appearance of a new measureable lesion (> 10 mm) on cross-sectional imaging or physical exam OR 2) enlargement of previously detected lesions on two consecutive imaging studies OR 3) enlargement of a previously detected lesion with correlative symptomatology on one cross-sectional imaging study; patients remain eligible if they had a previous response to a PD-1 inhibitor, including patients who had a complete response, partial response or stable disease; primary progressing patients are defined as those who received anti-PD-1 therapy within 2 months of study enrollment; patients with relapsed disease are defined as those who received their last dose of PD-1 blocking antibody >= 2 months prior to enrollment
Patients who received adjuvant PD-1 therapy who then develop measurable disease are eligible; however, they must have received their last dose of PD-1/PD-L1 blockade within two months of enrollment in this trial; they will be stratified with patients who have progressive disease
Previously treated with a PD-1/PD-L1-blocking antibody or a histone deacetylase inhibitor
Have available evaluable archival tumor tissue for PD-L1 biomarker assessment; presence of PD-L1 antigen on tumors is NOT required for study entry
Patients who are receiving or have been treated with antibody to CTLA4 (e.g. ipilimumab), PD-1, PD-L1, CD137, or CD27 within the prior 12 months. Any patient who has had one or more of these therapies greater than 12 months prior and is clinically free of disease and totally recovered from toxicities related to those therapies can be eligible.
Grade 3 or 4 major organ immune-related adverse events (IRAEs) following treatment with anti-PD-1/PD-L1
Phase 2: Patients with histologically or cytologically confirmed diagnosis of one of the following and with progressive disease during or after treatment with a PD-1 or PD-L1-inhibitor:
For Cohort A: Subjects who have radiographically confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 based therapy;
Documented disease refractory to at least one PD1/PD-L1 (+/- CTLA-4) inhibitor treatment, or intolerance to these drugs
Meet criteria for either the acquired resistance OR the suboptimal benefit cohort\r\n* Acquired resistance is defined as (must both be met):\r\n** Prior benefit from anti-PD-1/PD-L1 therapy defined as a) prior response, and/or b) ? 5 months of stable disease (SD); intervening therapies are allowed\r\n** Progressive disease (PD) on recent scans\r\n* Suboptimal benefit is defined as (must both be met):\r\n** Prolonged stable disease ? 5 months OR suboptimal response (> 10% & < 50% shrinkage per Response Evaluation Criteria in Solid Tumors [RECIST] at any evaluation timepoint) \r\n** Ongoing stable disease on recent scans\r\n** Last treatment with an anti-PD-1/PD-L1 agent within 6 weeks prior to starting protocol treatment
Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy.
Patients with prior treatment with PD-1 or PD-L1 inhibitor
Disease progression on prior PD-1/PD-L1 therapy in any line. Subjects must have received a minimum of 4 doses of anti-PD-1/PD-L1 therapy. If subjects have received fewer than 4 doses of anti-PD-1/PD-L1 therapy, documented radiologic progression and sponsor approval is necessary prior to inclusion.
14 days for prior PD-1 therapy.
Prior treatment with any PD-1 or PDL-1 inhibitor
Systemic immunotherapy for metastatic NSCLC. Immunotherapy agents include, but are not limited to, agents targeting the PD1/PD-L1 axis (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab) or CTLA-4 (ipilimumab, tremelimumab) pathways.
Participants who have received previous immunotherapy for any cancer (excluding melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors
Prior treatment with a combination of cetuximab and a PD-1/PD-L1 inhibitor; prior treatment with cetuximab or a PD-1/PD-L1 inhibitor is allowed as long as not previously given in combination
Must be pembrolizumab/nivolumab refractory/resistant – defined as having received at least 2 doses of pembrolizumab (or 2 doses of nivolumab) with documented systemic disease progression on staging imaging; progressive disease (PD) will be defined as increase in tumor burden > 20% relative to nadir (minimum recorded tumor burden) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1; once PD is confirmed, initial date of PD documentation will be considered as the date of disease progression; patients can be enrolled at any time following initiation of PD-1 therapy up to 1 year
Patients receiving PD-1 therapy whose disease is responding or stable (as defined by RECIST v1.1)
Subjects should have PD-L1 expression (tumor proportion score [TPS] >= 50%, determined by the Food and Drug Administration [FDA] approved Merck 22C3 antibody PD-L1 test) in the first-line setting and have a TPS > 1% by 22C3 or equivalent PD-L1 expression by an approved immunohistochemistry (IHC) test, in the second-line setting in order to be eligible for pembrolizumab treatment on the current protocol; patients with < 1% PD-L1 expression are not eligible
Subjects may already be receiving PD-(L)1 (including pembrolizumab or other PD-[L]1 inhibitors such as nivolumab, atezolizumab, avelumab, durvalumab) for the treatment of systemic disease; systemic disease must be in complete remission or be stable by RECIST 1.1; a washout period of at least 3 weeks is required from the last dose of PD-(L)1 inhibitor
Documented progression of disease after initiation of therapy with OR lack of response to therapy with a PD-1- or PD-L1-targeting monoclonal antibody (pembrolizumab, nivolumab, etc) after at least 18 weeks; NOTE: This treatment could have been at any time prior to registration
No history of prior treatment with inhibitor of PD-1 or PD-L1 or PDL2
Prior systemic therapy directed at MIBC – prior systemic therapy directed at non-muscle invasive disease (i.e. superficial bladder cancer [T1]) is permitted provided treatments within this study’s exclusion criteria were not used (cisplatin, anti-PD1) / anti-PD-L1 antibodies, etc.)
Previous treatment with PD-1 or PD-L1 directed therapy
Patients in Cohort 2 (high PD-L1) must have >= 50% expression
Patients in Cohort 3 (low PD-L1) must have 0-49% expression
Administration of a PD-1 or PD-L1 inhibitor within 60 days prior to study registration
For patients who discontinued PD-1 or PD-L1 inhibiting therapy during response to therapy, disease progression must have occurred following at least 8 weeks of re-treatment with PD-1 or PD-L1 inhibiting therapy
Determination by the treating medical oncologist that the patient is a candidate to continue the PD-1 or PD-L1 inhibiting therapy that the patient was receiving at the time of the most recent progression
Other anti-cancer therapy administered between the time of tumor response to PD-1 or PD-L1 therapy and time of study enrollment\r\n* Note: Patients treated with a combination of PD-1 or PD-L1 inhibiting therapy and other immunotherapy are eligible; patients taking hormonal anti-cancer therapies or steroids for central nervous system (CNS) edema management that, in the opinion of the investigator, are appropriate to continue are eligible
Any prior PD-1/PD-L1 therapy-related adverse events (AE) that, in the opinion of the investigator, warrants exclusion from participation in this trial
Participant must have histologically confirmed hepatocellular cancer (HCC) that is advanced or metastatic and have archival tissue available for PD-L1, PD-L2 testing (NOTE: if participant has had prior radiotherapy to the liver, a mandatory fresh biopsy will need to be obtained since radiotherapy could affect PD-1/PD-L1 immune status)
Prior therapies for extracranial metastatic melanoma including chemotherapy, BRAFi/MEKi, cytokine or vaccine therapy as long as it did not include PD-1/PD-L1
Prior exposure to any immuno-oncology agents, including CD40/PD-1/PD-L1/CTLA-4 inhibitors (if any ambiguity, should be discussed with study principal investigator)
Participants previously treated with BRAF inhibitors (vemurafenib, dabrafenib, encorafenib), MEK inhibitors (selumetinib, trametinib, binimetinib, cobimetinib), and/or anti-PD1/PDL1 monoclonal antibodies for metastatic or unresectable disease; any other prior therapy will be allowed (including ipilimumab, adjuvant anti-PD1 therapy, high-dose IL-2)
Patients must have received platinum-based therapy with or without bevacizumab, but may not have received a PD-1, PD-L1 or PD-L2 inhibitor
Patients who have received previous immunotherapy with PD1 or CTLA4 antibodies are not eligible
Subjects must have progressed on or after previous platinum-based chemotherapy; subjects must have also progressed on or after receiving any single-agent PD-1 or PD-L1 inhibitor (including pembrolizumab) as their most recent therapy and must have had at least a 3-month PFS on this therapy
Subjects must be enrolled on the trial within 6 weeks of their last infusion of PD-1 or PD-L1 inhibitor therapy
Treatment with any investigational agent within 28 days prior to registration for protocol therapy with the exception of PD-1 or PD-L1 inhibitors
History of an immune-related toxicity requiring treatment with corticosteroids during prior PD-1/ PD-L1 inhibitor treatment
ADDITIONAL INCLUSION CRITERION FOR COHORT 1 (PD-1/PD-L1 INHIBITOR-NAIVE, CETUXIMAB-NAIVE) AND COHORT 2 (PD-1/PD-L1 INHIBITOR-REFRACTORY, CETUXIMAB-NAIVE):
ADDITIONAL INCLUSION CRITERION FOR COHORTS 2 AND 3 (PD-1/PD-L1 INHIBITOR-REFRACTORY):
PD-1/PD-L1 inhibitor-refractory patients must have documented disease progression after prior response to anti-PD-1/PD-L1 therapy (response defined as stable disease, partial or complete response)
ADDITIONAL EXCLUSION CRITERION FOR COHORTS 1 (PD-1/PD-L1 INHIBITOR-NAIVE, CETUXIMAB-NAIVE) AND 4 (CUTANEOUS):
Patient has received any prior immunotherapy with inhibitors of PD-1 or PD-L1
Prior treatment of PD-1 or PD-L1-directed immune checkpoint blockade is permitted if treatment was not discontinued due to disease progression or life-threatening adverse events per the investigators’ discretion (laboratory abnormalities alone with prior therapy will not exclude patients from this trial)
Patients may have received any number and type of prior treatment regimens for their NSCLC (aside from patients in arm A, who cannot have had PD-1/PD-L1 inhibitors)
Arm A: patients must be treatment naive to single agent PD-1/PD-L1 inhibitors including but not limited to durvalumab, pembrolizumab, atezolizumab, nivolumab, and avelumab\r\n* Arm B: patients’ tumor must be either refractory to or progressed on one of the above agents\r\nNOTE: Patients must be eligible to receive the next line of therapy and not be suspected of having pseudoprogression\r\n* Both cases are defined by initial progressive disease (PD) or PD after CR, PR, or SD using RECIST criteria, respectively
Arm B: patients must not have had prior exposure to combination treatment with PD-1/PD-L1 inhibitors and another systemic treatment\r\n* NOTE: radiation therapy and surgery do not count as combination treatment
Patients who are intolerant to PD-1/PD-L1 inhibitors and/or metformin are excluded
No treatment with prior sipuleucel-T, PD-1 inhibitor, MPDL3280A or any other PD-L1 inhibitor, taxane-based chemotherapy for metastatic disease
Prior treatment with ibrutinib or an anti-PD-1, or PD-L1 or PD-L2 agent or ipilimumab in the metastatic setting
Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor
Prior treatment with an agent that blocks the PD-1/PD-L1pathway
Prior exposure to PD-1 or PD-L1 inhibitors is not allowed
Participant must have an advanced solid tumor and must not be a candidate for surgical resection or other approved therapeutic regimen known to provide clinical benefit. For dose escalation, the participant may have been previously treated with a programmed cell death 1 (PD-I) targeting agent. For dose expansion, the participant must be PD-I/PD-L1 targeting agent naïve. For Combination, the participant must be have SCLC with progressive disease and have failed platinum containing therapy and be PD-1/PD-L1 targeting agent naïve.
Prior anti-PD-1/PD-L1 targeted therapy is NOT allowed; prior CTLA-4 therapy or CD40/CD40L targeted therapy is allowed
Prior therapy with an anti-PD-1/PD-L1 antibody or a TRAIL-DR5 antibody
Has received prior immunotherapy with agents that target PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD-137 agents, or if the subject has previously participated in Merck pembrolizumab clinical trials
Have a PD-L1 positive (either strongly or weakly) tumor as determined by the IHC 22C3 pharmDx test at the study site; if a patient’s initial tumor specimen is not classified as PD-L1 positive by the central laboratory, a newly obtained specimen (different from the sample previously submitted) may be submitted for testing; if the newer specimen is classified as PD-L1 positive by the study site, the patient meets this eligibility criterion
Prior treatment for CLL with CTLA-4, PD-1, PD-L1, or CD137 monoclonal antibody (mAb)
Patients must not have had prior treatment with nivolumab or any other PDL1 or PD-1 antagonists
For Phase 1b LY3300054 monotherapy or combination therapy, no prior treatment with a PD-1 or PD-L1 agent is allowed.
Prior chemotherapy or other systemic anticancer therapy within 4 weeks prior to start of olaparib treatment, 6 weeks for nitrosoureas or mitomycin. Exceptions include: Anti-hormonal treatment for ER positive or PR positive breast cancer is allowed until 7 days prior to treatment with olaparib, exposure to an investigational agent within 30 days or 5 half-lives (whichever is the longer) prior to start of olaparib treatment is not allowed, prior receipt of biologics targeting T cell co-regulatory proteins and/or immune checkpoints is not allowed. Examples include MEDI4736 or other PD1 or PD-L1 or PD-L2 inhibitors or anti-CTLA4 therapy, previous treatment with a PARP inhibitor, is not allowed.
Patients who have had prior systemic therapy with a PD-1 blocking antibody will be excluded
Grade 3 or 4 major organ immune-related adverse events (IRAEs) following treatment with anti PD-1/PD-L1
Prior PD-1- or PD-L1-directed therapy or any therapeutic cancer vaccine.
Prior treatment with specific pathway-blockers (PD-1/PD-L1)
Inclusion Criteria:\n\n        Adult male or female subjects with pathologically confirmed MDS who failed to respond,\n        relapsed after an initial response, or were unable to tolerate hypomethylating agents, ECOG\n        performance status of 0 - 2, and adequate organ and marrow function.\n\n        Exclusion Criteria:\n\n        Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment,\n        prior MAb against CTLA-4, PD-1, or PD-L1, alllogenic or haploidentical transplant, current\n        immunosuppressive medication or autoimmune or inflammatory disease.
Patients who have had prior therapy (BRAF inhibitors, ipilimumab, anti PD-1 antibody or anti PD-L1 antibody) or treatment naive patients are eligible as long as toxicity from therapy is grade =< 1 or at baseline
Patients who have been treated with prior PD-1 and PD-L1 agents
Patients can be either ipilimumab naïve or refractory to ipilimumab, defined as received at least two doses of ipilimumab and documented disease progression; patients who were re-treated with ipilimumab and patients who were on maintenance ipilimumab will be allowed to enter the trial as long as there is documented progressive disease (PD); progressive disease will be defined as increase in tumor burden > 25% relative to nadir (minimum recorded tumor burden) which is confirmed by repeat assessment no less than four weeks from the date of the first documented PD; once PD is confirmed, initial date of PD documentation will be considered as the date of disease progression; prior ipilimumab therapy must have been completed at least 12 weeks before study drug administration
PD-L1 expression in tumor tissue from any site is required for patients with NSCLC for entry into cohort 1; tumor tissue must be obtained after the last systemic therapy; PD-L1 expression will be analyzed by a Merck assay; for NSCLC cohort 2, patients may test PD-L1 negative or may be unevaluable for PD-L1 expression (i.e. insufficient tumor tissue); PD-L1 expression is not required for patients with melanoma, but melanoma patients are required to submit an extra-cerebral specimen for analysis, unless it is not feasible to obtain one
Has had prior treatment with any other anti-PD-1 or PD-L1 or PD-L2 agent or an antibody targeting other immune-regulatory receptors or mechanisms; examples of such antibodies include (but are not limited to) antibodies against indoleamine 2, 3-dioxygenase (IDO), PD-L1, interleukin-2 receptor (IL-2R), glucocorticoid-induced TNFR family related gene (GITR); prior ipilimumab, interleukin-2 (IL2), bevacizumab and adoptive cell therapy is allowed
Phase II PD-1/PD-L1 refractory subsets: Patients with confirmed disease progression within 1 year following initiation of PD-1/PD-L1 inhibitor therapy (patients must have received at least 2 doses of the PD-1/PD-L1 inhibitor). No prior cytotoxic therapy in the advanced setting is permitted. BRAF inhibition therapy is acceptable before immunotherapy where clinically indicated. CTLA-4-inhibition therapy is acceptable as a prior line of therapy or in combination with anti-PD-1 therapy.
Prior history of or active interstitial lung disease or pneumonitis, encephalitis, seizures, severe immune related adverse events with prior PD-1/PD-L1 containing treatments;
Received prior therapies targeting PD-1 or PD-L1
Newly diagnosed, metastatic NSCLC with a PD-L1 TPS ? 50% (as determined by central lab using the PD-L1 IHC 22C3 pharmDx kit) NOTE: Subjects with documentation of PD-L1 TPS ? 50% by IHC analysis using the 22C3 pharmDx kit will not require repeat PD-L1 testing by central laboratory; and
Subjects with progression on or after first-line platinum-based chemotherapy who have a PD-L1 TPS ? 1% (as determined by central laboratory using the PD-L1 IHC 22C2 pharmDx kit). Subjects with EGFR or ALK genomic tumor aberrations with progression on FDA-approved therapy for these aberrations are eligible NOTE: Subjects with documentation of PD-L1 TPS ? 1% by IHC analysis using the 22C3 pharmDx kit will not require repeat PD-L1 testing by central laboratory;
Patients whose tumors have PD-L1 expression in >= 50% of tumor cells must have demonstrated progression on or intolerance to pembrolizumab; otherwise, patients who are eligible to receive an FDA-approved anti-PD-1/anti-PD-L1 agent as second-line therapy must also have demonstrated progression on or intolerance to the drug
PD on first-line therapy.
Either known PD-L1 expression at the time of treatment (measured using any FDA approved test) or PD-L1 expression demonstrated using the Ventana SP142 assay in a biopsy taken prior to the start of treatment
Part 2: Has received prior therapy with cancer vaccines, or compounds targeting PD-1 (including Merck pembrolizumab [MK-3475]), PD-L1, PD-L2, CTLA-4, lymphocyte-activation gene 3 (LAG-3), CD-137, OX-40 (tumor necrosis factor receptor superfamily, member 4 [TNFRSF4], also known as CD134), cluster of differentiation 40 (CD-40), glucocorticoid-induced TNFR-related protein (GITR), serine/threonine-protein kinase B-Raf (BRAF), MEK or other molecules in the MAPK pathway.
Has received prior treatment with PD-616 or low-dose cytarabine.
With the exception of CRPC and mBC patients, patients should have received prior PD-1 / PD-L1-containing checkpoint inhibitor therapy administered as their most recent therapy and have failed to achieve a PR or CR within four (4) months of starting that therapy;
Experienced PD during participation in another Valor study
Enrolled patients may be candidates for standard of care therapy with trabectedin or second line/subsequent line treatment for advanced disease with PD-1/PD-L1 inhibitor monotherapy; otherwise they should have no standard of care option available or be felt appropriate for a phase I clinical trial in the opinion of the treating investigator; prior PD-1/PD-L1 exposure is not an exclusion criteria
Prior treatment with an agent that blocks PD-1/PD-L1 pathway or other immune modulating agents within fewer than 4 weeks of 4 half-lives
Any number of prior systemic therapeutic regimens including chemotherapy, pathway inhibitors, biochemotherapy, investigational agents, and immunotherapies other than ipilimumab, nivolumab or other CTLA-4, PD-1 or PD-L1 inhibitors
Prior PD-1- or PD-L1-directed therapy.
Have experienced disease progression during treatment with an anti-PD1/L1 antibody as the treatment regimen immediately prior to accrual to this study or disease progression within 6 months of adjuvant anti-PD1 antibody
Patients must have received or be ineligible for platinum based chemotherapy and must have received at least one line of therapy with a PD-L1 or PD-1 targeting agent
Subjects must have had clinical benefit while on a PD-1 or PD-L1 inhibitor defined as at least a 3 month PFS, and now have disease progression.
Most recent PD-1 or PD-L1 inhibitor infusion must be completed at least 6 weeks of randomization. The subject must have recovered from all reversible acute toxic effects (other than alopecia) to =< grade 1 or baseline.
Previous discontinuation from PD-1 or PD-L1 due to an adverse event.
Patient with strong PD-L1 expression (>= 50% of tumor cells expressing PD-L1 ot or tu or TPS >= 50% ) will be excluded; patient’s with unknown PD-L1 expression or when PD-L1 expression can’t be determine
Prior treatment with a PD-1, PD-L1, or PD-L2 blocking therapy
Patients must not be on any other systemic therapy within the following intervals before study enrollment:\r\n* 1 week after stereotactic radiosurgery of the brain or comparable technology\r\n* 4 weeks after cytotoxic chemotherapy or external beam radiation therapy\r\n* 6 weeks after chemotherapy regimens including BCNU (carmustine) or mitomycin C\r\n* Patients who experience melanoma progression (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) while on or after treatment with programmed cell death 1 (PD-1) or PD ligand-1 (PDL-1) antibody may enroll on this study\r\n** NOTE: Patients must be off PD-1/PDL- antibody for at least 2 weeks to assess for delayed toxicity before being enrolled and receiving INCB024360; patients who are enrolled 2 weeks and up to 6 weeks after the last dose of PD-/PDL-1 antibody will enroll in cohort B and receive 100 mg BID of INCB024360; patients enrolled beyond the 6 week period after failing anti-PD-1/PDL-1 will be enrolled in cohort A; cohort A patients will receive 300 mg BID of INCB024360; patients must not have active grade 2 autoimmune toxicities attributed to these antibodies at study entry\r\n* 8 weeks after ipilimumab, other cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody or other immunologically active antibody\r\n** NOTE: Patients receiving prior CTLA-4, anti-PD1 antibody or other immunologic therapy must show evidence of normal pituitary function at baseline and must not have active grade 2 autoimmune toxicities attributed to these antibodies at study entry
Current or history of systemic autoimmune disease requiring systemic therapy, including significant autoimmunity associated with prior ipilimumab therapy or therapy with antibodies to PD-1 or PD-L1
Subjects may not have been previously treated with talimogene laherparepvec, any other oncolytic virus, pembrolizumab, or any other inhibitor of PD-1, PD-L1, or PD-L2.
Primary refractory melanoma: Subjects must have received prior treatment with anti-PD-1 or anti-PD-L1 therapy (alone or as part of a combination) in the advanced or metastatic setting and have progressive disease as their best response to treatment that is confirmed 4 weeks later.
Relapsed melanoma: Subjects must have received prior anti?PD-1 or anti?PD-L1 therapy (alone or as part of a combination) in the advanced or metastatic setting and achieved partial response ore complete response but later have confirmed progressive disease.
Patients must not have received neoadjuvant treatment for their melanoma; patients must not have had prior immunotherapy including, but not limited to ipilimumab, interferon alfa-2b, high dose IL-2, pegylated (PEG)-IFN, anti-PD-1, anti-PD-L1 intra-tumoral, or vaccine therapies; patients must not be planning to receive any of the prohibited therapies during the screening or treatment phases of the study
Unless unavailable, must have received at least one of cabozantinib or nivolumab (or other active anti-PD-1/PD-L1 therapy)
Must have disease progression on a prior PD-1-pathway targeted agent.
Must have had documented disease progression while on a prior PD-1 pathway-targeted agent.
Had prior treatment with any other anti-programmed cell death-1 (PD-1), or PD-ligand 1 (PD-L1) or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Has participated in any other pembrolizumab study and has been treated with pembrolizumab.
b. In Part 2SA, patients with an inadequate response to anti-PD-1 mAb therapy, defined as SD or PD using RECIST v1.1 criteria following at least 2 months of therapy. Patients with PD have a tumor measurement increase of < 2 fold from the time of starting anti-PD-1 therapy, must not have worsening of Eastern Cooperative Oncology Group (ECOG) performance status due to their disease progression, and cannot have new CNS lesion. Patients must also meet the lactic acid dehydrogenase (LDH) or ECOG status. No tumor size criteria are used in Part 2SA.
Prior therapy with any antibody/drug targeting T-cell coregulatory proteins (immune checkpoints) such as antiprogrammed death 1 (PD-1), anti-PD-L1, or anticytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody; for Part B, the Investigator must consult with the Medical Monitor and consider other co-regulatory targets such as 4-1BB
Participants without a PD-L1 test result are eligible for the study
Subject who received any prior monoclonal antibodies against PD-1 or PD-L1 and/or any prior:
For the expansion stage, evaluable for PD-L1 expression
Prior therapies targeting PD-1 or PD-L1.
Subjects who fail to meet enrollment criteria for other PD-1 or PD-L1 trials solely due to low or negative predictive biomarkers.
Tumor specimen is not evaluable for PD-L1 expression by the central laboratory
No prior CTLA-4 or PD-1/PD-L1 therapy for the treatment of metastatic disease
Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy.
Patients who have received prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy) within 2 weeks prior to registration; hormone therapy is permitted until registration\r\n* Note: patients who received prior anti-PD-1, PD-L1 or PD-L2 agents are still eligible; a wash-out period of 2 weeks prior to registration is required
Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.
Prior treatment with atezolizumab or another PD-L1/PD-1 therapy
Has received one prior systemic therapy regimen for metastatic renal cell carcinoma (mRCC) directed against PD-1 and/or PD-L1 which must have been the most recent regimen\r\n* Prior high-dose interleukin-2 therapy is permitted in addition to anti-PD(L)1 therapy, but is not required\r\n* Prior bevacizumab or vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) is permitted either in combination with anti-PD(L)1 therapy OR as monotherapy when given PRIOR to anti-PD(L)1 therapy\r\n* Prior treatment with combined ipilimumab and nivolumab is permitted\r\n* Prior axitinib in any setting is not permitted
Particpant has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanism, including participation in any other pembrolizumab trial and treatment with pembrolizumab. a. Examples of such antibodies include (but are not limited to) antibodies against indoleamine 2,3-dioxygenase (IDO), PD-L1, IL-2R, glucocorticoid-induced tumor necrosis factor receptor (GITR).
Part B: Anti-PD-1 non-responders are defined as those showing disease progression according to RECIST v1.1 after at least 12 weeks of therapy with a PD-1 antibody either alone or in combination with approved checkpoint inhibitor or targeted therapies according to their label; there is no serological requirement
Nonresponsive to most recent therapy (stable disease only or PD while on treatment), or
For patients in the pazopanib hydrochloride (pazopanib) cohort, no prior systemic therapy for mRCC is allowed, with the exception of prior cytokine therapy (such as interleukin-2, IFN-a), immunotherapy (such as anti-PD-1 or anti-PD-L1), or supportive therapies (such as zoledronic acid, denosumab)
ONLY FOR PART B – PD-L1 selection should a PD-L1 expression threshold have been defined in Part A and potentially additional mesothelioma trial data; there will be no PD-L1/biomarker selection for Part A
Prior therapy with a PD-1, PD-L1, or CTLA-4 inhibitor or a lung cancer-specific vaccine therapy
Confirmed PD-L1-negative SCCHN by Ventana SP263;
Subjects who have received prior therapy with regimens containing CTLA-4, PDL-1, or PD-1 antagonists are NOT permitted to enroll unless all of the following apply:
Prior systemic therapy targeting PD-1: PD-L1 axis.
Has received prior therapy with compounds targeting programmed death (PD)-1, PD-L1, PD-L2, or a mitogen-activated protein kinase (MAPK) pathway inhibitor
Have documented objective radiographic or clinical disease progression after PD-1/PD-L1 +/- anti-CTLA-4 inhibitor therapy (melanoma) or after at least 1 line of chemotherapy for metastatic disease (TNBC)
Has received prior therapy with PD-1, PD-L1, or CTLA-4 inhibitor
Ten patients with a diagnosis of NSCLC who have disease progression per investigator's assessment who are on anti PD-1 or PD-L1 therapies will be allowed to enroll in the phase II part of this study but must be switched to treatment per this protocol
Patients who have had chemotherapy or radiotherapy within14 days prior to entering the study; patients may not be currently receiving any other investigational agents or immunomodulatory agents (e.g. ipilimumab); patients treated with prior PD-1 or PD-L1 directed therapies are ineligible for the phase I portion
For Part 1b: Must have documented confirmed disease progression on a prior PD-1 pathway targeted agent or must be PD-1 pathway-targeted treatment naïve.
Subjects who have received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists may be permitted to enroll under certain conditions
Previously treated with a histone deacetylase inhibitor (i.e., vorinostat, belinostat, romidepsin, panobinostat), PD-1/PD-L1-blocking antibody (i.e., atezolizumab, nivolumab, pembrolizumab), or a cytotoxic T-lymphocyte associated protein-4 (CTLA-4) agent
Prior therapy with single agent nivolumab, pembrolizumab or other PD-1/PD-L1 antibody or prior therapy with ipilimumab/CTLA-4 antibody for metastatic/unresectable disease is allowed unless they have received it as combination immunotherapy. Patients who received these agents in the adjuvant setting may be enrolled, provided it has been at least 3 months since receiving therapy
Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.
All patients must have received at least one line of systemic therapy in the metastatic setting; prior immunotherapy is allowed, including prior treatment with nivolumab, another PD-1 inhibitor, or a PD-L1 inhibitor, as long as the reason for discontinuation of a prior PD-1 pathway inhibitor was not for drug-related toxicity
Subject has received PD-1/PD-L1 blockade or has been informed of the results of relevant positive Phase 3 trials with these agents.
Cohort 1 (combination of niraparib and PD-1 inhibitor): patients must have tumors with high PD-L1 expression (TPS ? 50%) per local assessment; with no known EGFR sensitizing mutation and/or ROS-1 or ALK translocations, and no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment for metastatic NSCLC
Cohort 2 (combination of niraparib and PD-1 inhibitor): patients must have tumors with PD-L1 expression (TPS between 1% and 49%) per local assessment, with no known EGFR-sensitizing mutation and/or ROS-1 or ALK translocation, and no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment for metastatic NSCLC
Cohort 3 (single agent niraparib): patients must have metastatic sqNSCLC and have progressed after both prior platinum-based chemotherapy and prior PD-1 or PD-L1 inhibitor treatment
NSCLC Cohorts (CIT-Naïve): Participants with histologically confirmed incurable, advanced NSCLC not previously treated with anti-PD?L1/PD-1 and/or with anti-CTLA?4 (investigational or approved), for whom a clinical trial of an investigational agent in combination with an anti-PD?L1/PD-1 antibody is considered an acceptable treatment option (if CIT [including anti-PD?L1/PD-1 agents] is approved as treatment for NSCLC by local regulatory authorities).
Urothelial carcinoma (UC) Cohort (CIT-Naïve): Participants with histologically confirmed incurable, advanced transitional cell carcinoma of the urothelium including renal pelvis, ureters, urinary bladder, and urethra, not previously treated with anti-PD-L1/PD-1 with or without anti-CTLA-4 (investigational or approved), for whom a clinical trial of an investigational agent in combination with an anti-PD?L1 antibody is considered an acceptable treatment option, if CIT (including anti-PD?L1/PD-1 agents) is approved as treatment for UC by local regulatory authorities
Prior treatment with an agent that blocks the PD-1/PD-L1 pathway
Completion of PD-L1 testing\r\n* Patients will be stratified as PD-L1 >= 5% versus (vs) < 5% OR inevaluable; baseline tumor will be utilized; if this returns inevaluable, efforts should be made to utilize the resected specimen
Has had treatment a prior monoclonal antibody targeting PD-1, PD-L1, PD-L2, or CTLA-4
Previous treatment with eribulin mesylate or any anti-PD-1, PD-L1, or PD-L2 agent or participation in any MK-3475 Merck studies
Patients must NOT have received any class of drugs targeted to the PD-1/PD-L1 pathway
Melanoma (anti-PD-1/PD-L1 therapy naïve or pre-treated)
Non small cell lung cancer (anti-PD-1/PD-L1 therapy naïve or pre-treated)
Renal Cell Carcinoma (anti-PD-1/PD-L1 therapy naïve or pre-treated)
Prior participation in an interventional, investigational cancer vaccine or immunotherapy study except for an anti-PD-1/PD-L1 study.
Chemotherapy, or immunotherapy or any other systemic anticancer therapy =< 3 weeks prior to study drug administration date; patients receiving anti-PD-1 treatment, and continue to receiving this treatment in combination with selinexor (Arms L and M), can start receiving the selinexor and anti-PD-1 combination without washout of the prior anti-PD-1 antibody
Patients with planned laparoscopic PD
No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4
Previous treatment with rociletinib or MPDL3280A, or other 3rd generation EGFR TKI (eg, AZD-9291, HM61713), or PD 1 axis targeted therapy (eg, anti PD 1 or anti-PD L1)
Having received any prior MAb (monoclonal antibodies) against CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1, or PD-L1 or having received other investigational MAbs (monoclonalantibodies) within 6 months
Prior use of systemic checkpoint inhibitors (including PD-1, PD-L1, and CTLA-4 targeting agents) for the management of ACC, non-urothelial bladder cancer/upper tract, non-adenocarcinoma prostate cancer, penile cancer or treatment refractory germ-cell tumor is excluded
Patients treated with PD-1 or PD-L1 inhibitors, CDK 4/6 inhibitors, or other immune-based therapy are eligible
Prior exposure to PD-1 or PD-LI treatment
Has received prior treatment with PD-1/PD-L1 pathway inhibitors in the adjuvant setting
Eligible for with plan to undergo neoadjuvant treatment with atezolizumab followed by surgery as part CC# 14524, or planned to undergo treatment with anti-PD-1 or anti-PD-L1 per standard of care
Previous exposure to CD40, PD-1, PD-L1, CTLA-4 antibodies or any other immunomodulatory agent
Prior therapy with an agent that blocks the PD-1/PD-L1 pathway
No evidence of PD for ?3 months before the first dose of study drug.
